Maysiglu (Sitagliptin)

Sitagliptin works by selectively blocking the DPP‑4 enzyme, which normally breaks down the incretin hormones GLP‑1 and GIP. Inhibition of DPP‑4 raises the levels of these hormones, leading to glucose‑dependent insulin release and reduced glucagon secretion, thereby improving overall glycaemic control.

The appropriate dose of Maysiglu is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function and response to therapy. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose without medical advice.

Safety data for sitagliptin in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Maysiglu. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maysiglu (sitagliptin) belongs to the DPP‑4 inhibitor class, which differs from GLP‑1 receptor agonists that are injectable and often produce more weight loss. Compared with other oral DPP‑4 inhibitors such as saxagliptin or linagliptin, sitagliptin has a similar efficacy and safety profile, with dosing convenience of once‑daily administration.

Maysiglu tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from excess moisture, heat and direct sunlight to maintain potency throughout its shelf life.

Maysiglu is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the specific instructions given by their prescriber regarding timing relative to meals.

The most serious adverse events associated with sitagliptin include acute pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin conditions like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling of the face or throat, or any other concerning symptoms.

Maysiglu should be avoided in individuals with known hypersensitivity to sitagliptin or any component of the formulation. Caution is also advised for patients with severe renal impairment, a history of pancreatitis, or significant cardiovascular disease, and the drug should only be used under medical supervision in these groups.